Cardiff has a cash runway of 5-6 quarters, but will need additional funding, potentially leading to significant shareholder ...

Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS, ...

A new case report was published in Oncotarget's Volume 15 on October 11, 2024, entitled "A case of adenosquamous pancreatic ...

Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the trea ...

Recent research from the University of Helsinki sheds new light on the behavior of the KRAS gene in two of the deadliest cancers—pancreatic and colorectal cancer. These findings suggest ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Batsmen have forgotten to play with soft hands because in T20 cricket they are used to muscling the ball, says head coach ...

If approved, Verastem expects that avutometinib plus defactinib will be the first-ever FDA-approved treatment specifically for adult patients in the United States with recurrent KRAS mutant LGSOC.

SOS1 is a guanine nucleotide exchange factor (GEF) that activates KRAS, and recent preclinical studies have demonstrated that combining KRAS and EGFR inhibitors with SOS1 inhibitors can overcome ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the ...

“ALTA3263 induces deep and durable tumor regressions in preclinical models addicted to the most common KRAS mutations, G12D, G12V, and G12C,” said Eric Murphy, Ph.D., co-founder and CEO of ...